MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 12-15-2022
OncoSec Medical Incorporated Accounts Payables 2011-2026 | ONCS
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Quarterly Accounts Payables OncoSec Medical Incorporated
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 838 K | - | - | 1.12 M | - | 799 K | 729 K | 729 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 M | 729 K | 843 K |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Ultragenyx Pharmaceutical
RARE
|
31 M | $ 19.23 | -3.85 % | $ 1.9 B |  USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
939 M | $ 742.02 | -1.94 % | $ 77.6 B | USA |
 |
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Replimune Group
REPL
|
12.5 M | $ 7.22 | -4.24 % | $ 582 M | USA |
 |
REGENXBIO
RGNX
|
21.4 M | $ 7.88 | -4.6 % | $ 406 M | USA |
 |
Aileron Therapeutics
ALRN
|
3.98 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
13.3 M | - | -6.81 % | $ 3.04 B | USA |
 |
Rigel Pharmaceuticals
RIGL
|
7.19 M | $ 26.2 | -0.64 % | $ 471 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
155 K | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
1.74 M | - | -11.76 % | $ 5.79 M | USA |
 |
Avidity Biosciences
RNA
|
12.4 M | $ 13.09 | -0.08 % | $ 1.8 B | USA |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
18.5 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M |  Canada |
 |
Avid Bioservices
CDMO
|
20.7 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
13.9 M | $ 78.52 | -4.13 % | $ 5.1 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
6.47 M | $ 12.57 | -9.96 % | $ 1.91 B | USA |
 |
Sana Biotechnology
SANA
|
1.67 M | $ 2.78 | -8.42 % | $ 704 M | USA |
 |
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
825 K | $ 5.35 | 7.76 % | $ 383 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
116 M | $ 321.71 | -1.96 % | $ 42.1 B | USA |
 |
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
11.6 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
6.75 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
463 K | $ 1.08 | -0.92 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
12.6 M | - | - | $ 40.5 M | USA |